Balancing the benefits of antimicrobial therapy with the threat of antimicrobial resistance development

J Cyst Fibros. 2021 May;20(3):377-378. doi: 10.1016/j.jcf.2021.04.009.

Authors

Andrew Lee¹, Deirdre Gilpin²

Affiliations

¹ Halo Research Group, Queen's University Belfast, Belfast, UK; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. Electronic address: [email protected].
² Halo Research Group, Queen's University Belfast, Belfast, UK; School of Pharmacy, Queen's University Belfast, Belfast, UK.

PMID: 34103153
DOI: 10.1016/j.jcf.2021.04.009

No abstract available

Publication types

Editorial

MeSH terms

Anti-Bacterial Agents / therapeutic use*
Cystic Fibrosis / microbiology*
Drug Resistance, Bacterial*
Humans

Substances

Anti-Bacterial Agents